Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REGENXBIO Hunts For 2025 Gene Therapy Approval

Executive Summary

The group’s gene therapy reduces saccharide levels in the rare childhood disease known as Hunter syndrome, but a confirmatory trial will be needed.

You may also be interested in...



Taking On Vyvgart In Myasthenia Gravis

Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.

Remibrutinib REMIXes The Itch Record

Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.

GSK Counters Innoviva’s Gonorrhea Hit

Both groups have posted hits with similar novel antibiotics, and both have a lot riding on commercial success.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel